GALAPAGOS NV |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.1 EUR | -1.02% |
|
-4.84% | -26.68% |
| Sales 2024 * | 337M 359M | Sales 2025 * | 314M 334M | Capitalization | 1.8B 1.92B |
|---|---|---|---|---|---|
| Net income 2024 * | -44M -46.81M | Net income 2025 * | -65M -69.16M | EV / Sales 2024 * | -4.83 x |
| Net cash position 2024 * | 3.43B 3.65B | Net cash position 2025 * | 3.13B 3.33B | EV / Sales 2025 * | -4.21 x |
| P/E ratio 2024 * |
-28.6
x | P/E ratio 2025 * |
-21
x | Employees | 1,123 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.64% |
More Fundamentals
* Assessed data
More news
Latest transcript on Galapagos NV
More recommendations
More press releases
More news
| 1 week | -5.13% | ||
| Current month | -7.44% | ||
| 1 month | -11.65% | ||
| 3 months | -21.10% | ||
| 6 months | -15.68% | ||
| Current year | -25.98% |
1 week
26.94
28.64
1 month
26.9431.19
Current year
26.9439.00
1 year
26.9441.92
3 years
26.9469.82
5 years
26.94252.90
10 years
10.00252.90
| Managers | Title | Age | Since |
|---|---|---|---|
Paulus Stoffels
CEO | Chief Executive Officer | 62 | 22-03-31 |
Thad Huston
DFI | Director of Finance/CFO | 54 | 23-05-31 |
| Investor Relations Contact | - | 20-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Andrew Dickinson
BRD | Director/Board Member | 54 | Mar. 26 |
Jérôme Contamine
BRD | Director/Board Member | 66 | 22-04-25 |
Simon Sturge
BRD | Director/Board Member | 65 | 23-09-18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.28% | 22 M€ | -0.67% | ||
| 0.03% | 773 M€ | -.--% | - | |
| 0.01% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 27.1 | -1.02% | 33 661 |
| 24-04-18 | 27.38 | 0.00% | 135,801 |
| 24-04-17 | 27.38 | -1.16% | 104,556 |
| 24-04-16 | 27.7 | -1.56% | 82,849 |
| 24-04-15 | 28.14 | -1.26% | 89,376 |
Real-time Euronext Amsterdam, April 18, 2024 at 11:35 am EDT
More quotes
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. The company is committed to improving patients' lives worldwide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.
Calendar
2024-04-30
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
27.38
EUR
Average target price
38.43
EUR
Spread / Average Target
+40.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -25.98% | 1.92B | |
| -1.82% | 41.35B | |
| +44.25% | 40.38B | |
| +2.56% | 39.05B | |
| -12.11% | 26.67B | |
| +3.09% | 24.07B | |
| -24.16% | 18.36B | |
| +22.12% | 11.6B | |
| -3.74% | 11.68B | |
| +7.75% | 11.15B |
- Stock Market
- Equities
- GLPG Stock
